BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Xenogen Corporation (XGEN) Files Answer And Counterclaims In Patent Infringement Litigation With AntiCancer


10/19/2005 5:10:20 PM

ALAMEDA, Calif., May 10 /PRNewswire-FirstCall/ -- Xenogen Corporation , maker of advanced imaging systems including instruments, biological solutions and software to accelerate drug discovery and development, today announced that it filed with the court its answer to a patent infringement complaint filed by AntiCancer Inc. Concurrent with filing its answer, Xenogen filed counterclaims against AntiCancer claiming that AntiCancer infringes two Xenogen patents.

On March 7, 2005, AntiCancer filed a lawsuit against Xenogen in the U.S. District Court for the Southern District of California alleging infringement of five patents of AntiCancer relating to fluorescence-based imaging. The complaint does not specify the factual basis of the allegedly infringing conduct. The complaint seeks damages and injunctive relief against the alleged infringement. On March 29, 2005, AntiCancer amended its complaint to include an additional claim seeking a judgment that one of Xenogen's imaging patents, 5,650,135, is invalid.

On May 10, 2005, Xenogen filed its answer to AntiCancer's amended complaint. Xenogen denied all of AntiCancer's allegations and asserted various affirmative defenses, including its position that AntiCancer's patents, including some of the patents cited in its complaint, and patent claims relating to in vivo imaging of fluorescence, are invalid. Xenogen is vigorously defending itself against AntiCancer's claims and believes AntiCancer's complaint is without merit

Concurrent with filing its answer to AntiCancer's complaint, Xenogen filed its own counterclaims against AntiCancer. Xenogen's counterclaims allege that AntiCancer infringes two of Xenogen's U.S. patents, 5,650,135 and 6,649,143, both relating to in vivo imaging and with a priority date before AntiCancer's patents cited in its amended complaint. Xenogen intends to vigorously pursue its claims against AntiCancer.

Xenogen and AntiCancer are also involved in litigation that commenced in 2001. In that lawsuit, AntiCancer alleges the following five causes of action against Xenogen: trade libel, defamation, intentional interference with contract, intentional interference with prospective economic advantage and unfair competition. A September 2005 trial has been scheduled for this lawsuit. Xenogen believes the complaint is without merit and it is mounting a vigorous defense.

These lawsuits may be expensive, take significant time and may divert Xenogen management's attention from other business concerns. The patent infringement lawsuits will put certain of Xenogen's patents at risk of being invalidated or interpreted narrowly. Additionally, Xenogen may suffer reduced instrumentation sales and/or license revenue as a result of the pending lawsuits or following final resolution of the lawsuits. Xenogen may not successfully defend itself against AntiCancer's claims, and could have monetary damages or other remedies levied against it that could adversely impact Xenogen's financial position or operations. Xenogen may not prevail in its patent infringement counterclaims against AntiCancer and any damage or other remedies awarded to Xenogen, if any, may not be commercially valuable. During the course of the lawsuits, there may be public announcements of results of hearings, motions and other interim proceedings or developments in the litigations. If securities analysts or others perceive any of these results to be negative, it could cause our stock price to decline.

About Xenogen Corporation

Xenogen combines systems biology and low-light optical imaging to create powerful new biophotonic imaging technology that advances the ability of scientists to explore genes, proteins, pathogens and tumor cells in living animals in real time, providing predictive data that is designed to substantially improve the success rate in drug development. Xenogen incorporates into living animals the bioluminescent gene that makes a firefly glow and harnesses the resulting light using an ultra-sensitive camera and sophisticated software. This biophotonic imaging technology creates images and analyzes the resulting data on cellular activity, gene expression, and spread of disease or the effect of a new drug candidate. Xenogen's biophotonic imaging technology is used by leading academics and pharmaceutical and biotechnology companies to provide more accurate and previously unavailable data that is intended to result in the ability to make more timely and cost-effective decisions at every step in the drug development process.

Xenogen Corporation

CONTACT: William A. Albright, Chief Financial Officer of XenogenCorporation, +1-510-291-6100, or Jim Byers or Jordan Goldstein, both ofFinancial Dynamics, +1-415-439-4500, both for Xenogen



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->